Key players include Novo Nordisk, Eli Lilly, and Pfizer
Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes
Oral semaglutide linked to significant weight loss as Novo Nordisk awaits FDA approval Oral semaglutide can help overweight and obese patients lose significant weight, according to new data published in The New England Journal of Medicine .[1] Semaglutide is a GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic
In most studies, the combination therapy was related to a significant reduction of the risk of MACE, heart failure, or death from any cause
Philis-Tsimikas A, Asong M, Franek E et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
Hepatic insulin sensitivity index (HISI) was calculated in the fasting state: HISI GPR = 1000 / [GPR (mg kg FFM 1 min 1 ) plasma insulin concentration (U/ml)] [24]
